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Abstract
Background: Mixed adenoneuroendocrine carcinoma is a rare tumor recently recognized as a new category in the
last World Health Organization (WHO) classification of appendiceal tumors (2010). This term has been proposed to
designate carcinomas of the appendix that arise by progression from a pre-existing goblet cell carcinoid. Mixed
adenoneuroendocrine carcinomas are more aggressive tumors than typical goblet cell carcinoids and usually
present with peritoneal spreading and ovarian masses. Staging, some histological features, and completeness of
surgery are factors that determine its evolution.
Case Presentation: We report the case of a mixed adenoneuroendocrine carcinoma—signet ring cell
subtype—that presented as a Krukenberg tumor of unknown primary.
Conclusion: The review of literature is focused on the most recent WHO pathologic classification of appendiceal
tumors containing goblet cell clusters, which seems to correlate with prognosis. A management proposal for mixed
adenoneuroendocrine carcinomas reported in previous literature is also discussed. This ranges from right
hemicolectomy to cytoreduction plus hyperthermic intraperitoneal chemotherapy, in both cases usually followed by
intravenous chemotherapy.
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Background
Mixed appendiceal adenoneuroendocrine carcinoma is
an extremely rare tumor recently recognized as an inde-
pendent entity in the last World Health Organization
(WHO) classification of appendiceal tumors, which dates
from 2010. This term has been proposed to designate
carcinomas of the appendix that arise by progression
from a pre-existing goblet cell carcinoid. Morphologic-
ally, it is composed of goblet cell clusters and carcinoma
cells, each component representing at least 30 % of the
tumor, showing important cytologic atypia [1].
Appendiceal malignant epithelial tumors account for
1 % approximately of all gastrointestinal neoplasms and
are mainly divided in neuroendocrine neoplasms and
carcinomas [2]. In the past, goblet cell carcinoids, or
formerly called “adenocarcinoids,” were considered a
category of the neuroendocrine neoplasms that in-
cluded all neoplasms containing goblet cell clusters [3].
However, the disparity of pathologic features and prog-
nosis leads Tang et al. in 2008 to propose a subclassifi-
cation of this category and to propose a differential
therapeutic algorithm [4]. Based on this research, the
2010 WHO classification of appendiceal tumors recognized
two separate entities, both considered to be neuroendo-
crine tumors: classic goblet cell carcinoids (GCCs) and
mixed adenoneuroendocrine carcinomas.
Goblet cell clusters, which are the neuroendocrine dis-
tinctive component of these two tumors, are small nests
of signet ring-like cells resembling normal intestine goblet
cells except for nuclear compression and atypia. These
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clusters show a characteristic submucosal growth that af-
fects the base of crypts and presents positivity for both
neuroendocrine and epithelial markers. While GCCs (def-
inition from 2010 WHO classification) are composed of
well-defined goblet cell clusters with mild to moderate
atypia, mixed adenoneuroendocrine carcinomas are con-
sidered more aggressive tumors. These are characterized
by significant atypia, partial loss of goblet cell clusters, and
presence of carcinoma cells with a wide range of differen-
tiation (from signet ring cell—SRC—to poorly differenti-
ated adenocarcinoma), without apparently any neoplastic
change in the mucosa [1, 4].
This report presents the case of a Krukenberg tumor
originated from an adenoneuroendocrine carcinoma and
reviews the literature about this extremely infrequent
histology and its management.
Case presentation
A 75-year-old woman without significant medical history
and an excellent performance status was diagnosed of a
87 × 73-mm solid right ovarian mass during a gynecologic
review. CA125, CA 199, and CEA were normal. A CT scan
excluded distant lesions. Laparoscopy revealed a white, en-
capsulated ovarian mass, resembling a thecoma, without
extraovarian implants. Hysterectomy and double adnexect-
omy were performed. Pathologists reported a SRC adeno-
carcinoma, invading all genital organs and showing
prominent lymphovascular permeation. Tumor growth in
Fig. 1 Ovarian masses. a Ovarian stroma. b Aggregates of mucin
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the ovarian stroma exhibited a nodular pattern (see Fig. 1a)
and irregular aggregates of mucin (Fig. 1b), suggesting a
mucinous Krukenberg tumor. Tumor cells were diffusely
positive for CK 20, focally positive for CK7, and negative
for estrogen receptors. Peritoneal washings were negative
for malignant cells. Several complementary exams were
performed but failed to detect an extraovarian primary
(fibrocoloscopy, fibrogastroscopy, PET-CT, mammogra-
phies). Two months later, the patient remained asymp-
tomatic, and appendectomy was planned to exclude a
primary appendiceal tumor. During this procedure, an
appendiceal mass and multiple peritoneal implants were
discovered. A complete cytoreductive surgery and right
hemicolectomy (RH) were finally performed. Pathologists
reported an appendiceal adenoneuroendocrine carcino-
ma—SRC type—invading peritoneum and one paraaortic
lymph node. Key points in the resected appendix, for
pathologic diagnosis, were the presence of goblet cell clus-
ters and SRC arranged in irregular large clusters, single-
cell infiltrating pattern and significant cytologic atypia
(Fig. 2a); destruction of the appendiceal wall (Fig. 2b); and
focal immunoreactivity for synaptophysin (Fig. 2c). Adju-
vant chemotherapy was delivered (FOLFOX, 12 cycles).
After 2 years, the patient is currently free of relapse.
Discussion
Mixed appendiceal adenoneuroendocrine carcinomas
and GCCs have been historically included in the same
category (referred as “adenocarcinoids” or simply “GCCs”)
because of the presence of goblet cell clusters, despite
the prognosis disparity reported in historical series.
Early studies of adenocarcinoids, the majority of them
reported in the 1970s and 1980s, pointed to their inter-
mediate features and prognosis between typical appen-
diceal carcinoids and colonic adenocarcinomas, as well
as their spectrum of goblet cell cluster percentage, mucine
amount, nuclear atypia, mitotic count, and metastatic
ability [5–12]. A review of 57 studies (including nearly
600 patients) found that 5-year overall survival ranged
between 60 and 84 % [13].
Present 2010 WHO pathologic classification of
appendiceal tumors differentiates GCC from adeno-
neuroendocrine carcinomas [1] based on morphologic
criteria developed by Tang et al., which were reported
in 2008 with high interobserver concordance [4]. The
authors classified 63 cases of appendiceal adenocarci-
noids collected from Memorial Sloan Kettering Cancer
Center between 1993 and 2005 into three categories:
typical GCC (group A, 30 cases), adenocarcinoma ex
GCC subtype SRC (group B, 26 cases), and adenocar-
cinoma ex GCC subtype poorly differentiated (group C,
7 cases). Group A tumors presented well-defined goblet
cell clusters with mild to moderate atypia. Group B
tumors were composed of goblet cells and SRC arranged
in irregular large clusters with partial loss of typical goblet
cell cluster architecture, significant atypia, single-cell infil-
trating pattern, and destruction of the appendiceal wall.
Group C tumors’ hallmark was the presence of at least
one foci that could not be distinguished from a poorly dif-
ferentiated adenocarcinoma or undifferentiated carcin-
oma. Extracellular mucin could be prominent in groups A
and B tumors. Remarkably, PET performed to our patient
had not detected peritoneal disease, probably due to the
Fig. 2 Appendiceal tumor. a Significant cytologic atypia. b Destruction
of the appendiceal wall. c Focal immunoreactivity for synaptophysin
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significant mucinous component of the tumor. Addition-
ally, all groups presented focal immunoreactivity for
neuroendocrine markers (chromogranin or synaptophy-
sin mainly); however, while groups A and B showed
normal expression of intestinal mucin glycoproteins
(MUC1−/MUC2+) and Ki67 < 20 %, group C had ab-
normal p53 expression, MUC1+/MUC2− pattern, and
Ki67 > 70 %. Previously, Alsaad had described strong
immunoreactivity for CK20 and inconsistent immuno-
reactivity for CK7 in a series on 17 appendiceal goblet
cell-containing tumors, similarly to colonic adenocarcin-
omas [14]. In the 2010 WHO classification, group A is re-
ferred as GCC and groups B and C are referred to as
mixed adenoneuroendocrine carcinomas.
Both GCC and mixed adenoneuroendocrine carcinomas
are thought to arise from a crypt base stem cell that will
develop both neuroendocrine and glandular differentiation
[15]. Adenoneuroendocrine carcinomas are considered to
be more aggressive forms developed from pre-existing
GCC. Interestingly, discordant histology between primary
appendiceal adenocarcinoids and their peritoneal implants
was reported in nine cases by Yan et al. in 2008 [16]. Peri-
toneal implants from these patients had lost the neuroen-
docrine component and goblet cell clusters, as ovarian
metastases in our case (Fig. 1). This phenomenon is con-
sistent with progression of GCC to the more aggressive
mixed adenoneuroendocrine carcinomas.
Median age of presentation of GCC and appendiceal
adenoneuroendocrine carcinomas ranges between the
fifth and sixth decades of life. The most common clinical
presentation is acute appendicitis (nearly or above 50 %
of cases). Other symptoms are abdominal pain, abdom-
inal mass, bowel obstruction, gastrointestinal bleeding,
or incidental finding [4, 6, 8, 10, 13, 17–20]. Tang et al.
found that abdominal pain plus lower abdominal palp-
able mass was the most frequent presentation (50 %),
followed by acute appendicitis (44 %) [4]. In a series of
16 appendiceal adenocarcinoids diagnosed between 1995
and 2005 in Mount Sinai Hospital, ten tumors had been
found incidentally [21].
Staging is based on the colonic adenocarcinomas sta-
ging system from American Joint Committee on Cancer
(AJCC) [18, 22]. In the series reported by Tang et al.,
pathologic classification correlated with staging and
prognosis. While 70 % of group A tumors presented
with stage I or II, 90 % of groups B and C presented
with stage IV and mesenteric nodal disease. Stages I
and II achieved an excellent survival after surgery with
or without chemotherapy. However, 5-year overall sur-
vival of patients with stage IV disease was 100, 38, and
0 % for groups A, B, and C, respectively [4].
Ovaries and peritoneum are the most common meta-
static sites for mixed adenoneuroendocrine carcinomas
[4, 6, 8, 10, 13, 17, 18, 21]. Up to 83 % of women with
stage IV disease present with ovarian masses [4].
Therefore, mixed appendiceal adenoneuroendocrine
carcinomas should be considered as possible origins of
Krukenberg tumors, whose definition is “ovarian me-
tastases from mucinous tumors with at least 10 % of
SRC component” [23, 24]. Distinction from a primary
ovarian tumor can be difficult because some primary
ovarian tumors can also contain SRC [25]. Significant
expansion of the ovarian stroma due to edema, fibrosis,
or cell proliferation is the main feature of Krukenberg
tumors, providing a macroscopic appearance similar to
our patient’s ovarian mass [26]. Krukenberg tumors ac-
count for 30–40 % of ovarian metastases [27]. Usual
primaries are gastrointestinal, biliary-pancreatic, or
breast [23]. Characteristics that suggest an extraovarian
origin rather than a primary ovarian neoplasm are bi-
lateralism, small size, nodular appearance, heterogen-
eity, destructive stromal invasion, surface implants, and
lymphovascular permeation [25]. Immunochemistry
may provide additional information. The pattern “diffuse
CK20+/focal CK7+” of our case suggested an appendiceal
origin [26]. Up to two thirds of Krukenberg tumors are
diagnosed without clinical evidence of the primary before
a surgical procedure [24]. Indeed, appendectomy is rec-
ommended in cases of Krukenberg tumors of unknown
primary. In a series reported in 2007 of 30 cases of
resected appendiceal tumors and ovarian metastases with
“GCC-like and SRC pattern,” diagnosed synchronous or
metachronous, most appendixes did not present a macro-
scopically measurable tumor [28].
Management of GCC and mixed adenoneuroendo-
crine tumors has been historically extrapolated from
treatment of appendiceal adenocarcinomas, for which
RH (with excision of regional lymph nodes) has long
been considered a standard [29, 30]; however, this issue
has importantly evolved in the last decade. Tang et al.
recommend customizing treatments to the new classifi-
cation [4]. Firstly, for pT1/pT2 typical GCC with nega-
tive margins, only surgery (appendectomy or RH) is
proposed as the standard of care. Reported retrospect-
ive studies of “adenocarcinoid tumors” suggest that RH
does not provide a survival benefit over appendectomy
(plus en bloc removal of mesoappendix) in some se-
lected patients [18, 21]; a meta-analysis of retrospective
data from 100 patients with “appendiceal adenocarci-
noid” supports the use of appendectomy as the pre-
ferred option for localized low-grade tumors with
negative margins and non-invaded base of appendix
[31]. Secondly, in case of SRC adenoneuroendocrine
carcinomas, pT3/pT4, perforated tumors, or positive
margins in the appendectomy, RH is the recommended
option, followed by intravenous—IV—chemotherapy in
stage III disease. And thirdly, in cases of poorly differ-
entiated adenoneuroendocrine carcinomas or in cases
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with intraperitoneal spread, cytoreduction plus hyperther-
mic intraperitoneal chemotherapy—HIPEC—followed by
IV chemotherapy [4] is the recommended option by these
researchers. HIPEC is arising as a new option for neo-
plasms with frequent peritoneal dissemination, which is
the main cause of death of these patients. Whether per-
forming (or not) HIPEC in our 75-year-old patient is a
controversial issue due to morbidity. Finally, taking into
account the high incidence of ovarian metastases from
GCC and mixed adenoneuroendocrine carcinomas, some
authors also recommend prophylactic oophorectomy
when resecting the primary tumor [4, 10, 13, 18].
Little evidence supports the use of IV chemotherapy,
though several case reports using different drugs are pub-
lished. Usual schemes are those used for colonic adenocar-
cinomas, which include 5FU, leucovorin, oxaliplatin, or
irinotecan [4, 13, 18, 29]. Similarly to typical neuroendo-
crine carcinomas, schemes with cisplatin plus etoposide
or 5-fluorouracil, cisplatin, and streptozotocin have also
been used [17].
Conclusions
In conclusion, and according to the last WHO classifica-
tion of gastrointestinal neoplasms, appendiceal tumors
containing goblet cell clusters are divided into GCC and
mixed adenoneuroendocrine carcinomas. The latter can
contain SRC or poorly differentiated carcinoma cells.
This classification correlates with staging and prognosis.
Mixed adenoneuroendocrine carcinomas behave more
aggressively than classic GCC and usually present with
peritoneal spreading and ovarian masses. A possible
presentation may be as a Krukenberg tumor of unknown
origin; in this case, appendectomy may be crucial to dis-
cover the primary. Their management may range from
RH to cytoreduction with HIPEC, usually followed by IV
chemotherapy.
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